Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Student of O. O. Bogomolets National Medical University, Kyiv, Ukraine.
Infect Disord Drug Targets. 2023;23(7):1-13. doi: 10.2174/1871526523666230509110907.
Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARSCoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used for not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss the characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.
瑞德西韦似乎是对抗严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染最有效的药物，并在全球范围内广泛用于治疗 2019 年冠状病毒病 (COVID-19) 患者。瑞德西韦是一种 RNA 聚合酶抑制剂，在 SARS-CoV、中东呼吸综合征 (MERS) 和 SARS-CoV-2 的体外和体内模型中具有广谱的抗病毒活性。瑞德西韦是美国食品和药物管理局 (FDA) 批准的第一种用于成人和儿科患者的抗 SARS-CoV-2 治疗药物，已用于未住院且患有轻度至中度 COVID-19 且有进展为严重 COVID-19（包括住院或死亡）高风险的患者。然而，人们对瑞德西韦治疗 COVID-19 的价值提出了质疑，世界各国监管机构一直犹豫不决批准这种药物。然而，在公共卫生紧急情况下，以及迫切需要为 COVID-19 患者提供有效治疗的情况下，瑞德西韦已被世界上几个当局批准。在这里，我们讨论了瑞德西韦的特点和应用，以及对其疗效的各种具有不同结果的具有挑战性的研究。
